AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium...

Related Keywords

Germany ,United Kingdom ,Massachusetts ,United States ,Italy ,Cambridge ,Cambridgeshire ,Ludwigshafen ,Rheinland Pfalz ,France ,Spain ,London ,City Of ,British ,Lou Gehrig ,Liz Shea ,Amber Landis ,Mudra Kapoor ,Prnewswire Abbvie ,Exchange Commission ,Foundational Neuroscience Center ,Allergan ,United Kingdom Or European Union ,Migraine Trust International Symposium ,International Study ,Standard Time ,Abbvie Abstracts ,Preventive Treatment ,Global Results ,Preventive Medication Failure ,Functioning Among Individuals ,Preventive Treatment Failure ,Effective Preventive ,Migraine Epidemiology ,Global Findings ,Diagnosis Rates ,Post Headache Phases ,Interim Results ,Migraine Attacks ,Chronic Migraine ,Activity Impairment ,Work Productivity ,Activity Impairment Questionnaire ,Migraine Specific Quality ,Life Questionnaire ,Headache Impact ,Oral Atogepant ,Acute Medication Overuse ,Responder Rates ,World Persistence ,Costs Among Patients ,Chronic Migraine Treated ,Retrospective Claims Analysis ,Reported Normal Function ,Satisfaction Are Maintained ,Long Term Intermittent Use ,European Union ,Important Safety Information ,Allergan Units ,Medication Guide ,Product Information ,Boxed Warning ,Neuroscience Discovery ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Abbvie ,